Safe use of statins in elderly people

Journal of Pharmacy Practice and Research

Volumn 44, Issue 3, 2014, Pages 138-142

  Westaway, Kerrie P ^a   Frank, Oliver R ^b,c   Husband, Alan J ^d   Rowett, Debra ^e,f   Rossi, Simone ^f,g   Blanc, Tammy L ^a   Shute, Russell ^f,g  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b Oakden Medical Centre   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d Medicines Information NPS MedicineWise   (Australia)

^e REPATRIATION GENERAL HOSPITAL   (Australia)

^f Veterans' Medicines Advice and Therapeutics Education Services (Veterans' MATES) Writing Group   (Australia)

^g Australian Medicines Handbook   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; GERIATRIC PATIENT; HUMAN; MUSCLE DISEASE; MYALGIA; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; QUALITY OF LIFE;

EID: 84929992205     PISSN: 1445937X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jppr.1022     Document Type: Article

References (19)

1. 1 Morgan T, Williamson M, Pirotta M, Stewart K, Myers S, Barnes J. A national census of medicines use: a 24-hour snapshot of Australians aged 50 years and older. Med J Aust 2012; 196: 50-3.
2. 2 Blom D. Statin therapy for the octogenarian? J Endocrinol Metab Diabetes South Afr 2012; 17: 37-42.
3. 3 Therapeutic Guidelines. Cardiovascular. Version 6. Melbourne: The Therapeutic Guidelines Ltd; 2012.
4. 4 Naci H, Brugts J, Fleurence R, Tsoi B, Toor H, Ades A. Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials. Eur J Preo Cardiol 2013;20:641-57. DOI: 10.1177/2047487313480435.
5. 5 Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
6. 6 Mills E, Wu P, Chong G, Ghement I, Singh S, Akl E, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network metaanalysis of 170 255 patients from 76 randomized trials, Q J Med 2011; 104: 109-24.
7. 7 National Vascular Disease Prevention Alliance. Guidelines for the management of absolute cardiovascular disease risk. 2012 Available from http://strokefoundation.com.au/health-professionals/clinical-guidelines/guidelines-for-the-assessment-and-management-ot-absolute-cvd-risk/.
8. 8 Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376:1670-81.
9. 9 Australian Medicines Handbook. Australian Medicines Handbook. Adelaide: Australian Medicines Handbook Pty Ltd; 2013.
10. 10 Chatzizisis Y, Koskinas K, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou G. Risk factors and drug interactions predisposing to statin-induced myopathy. Implications for risk assessment, prevention and treatment. Drug Saf 2010; 33: 171-87.
11. 11 Parikh S, Sharkey K, Workman B. Cardiovascular risk reduction in the extremely elderly. J Pharm Pract Res 2013; 43: 62-8.
12. 12 Mansi I, Prei C, Pugh M, Makrisk U, Mortensen E. Statins and musculoskeletal conditions, arthropathies, and injuries. fAMA Intern Med 2013; 173: 1-10. DOI 10.1001/jarnainternmed.2013.6184.
13. 13 NPS News 71. Managing lipids, reducing cardiovascular risk. 2011. Available from http://www.nps.org.au/publications/health-professional/nps-news/2011/lipids. Accessed 15 May 2013.
14. 14 Law M, Wald N, Rudnicka A. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326: 142.3-7.
15. 15 Rogers S, Magliano D, Levison D, Webb K, Clarke P, Grobler M, et al. A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin. Clin Titer 2007; 29: 242-52.
16. 16 Weng T, Yang Y, Lin S, Tai S. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 2010; 35: 139-51.
17. 17 Australian Government. Department of Health and Ageing. Pharmaceutical Benefits Scheme. Review of statin therapies 2012. Available from http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2012-07/review-of-statin-therapies, Accessed 12 June 2013.
18. 18 Australian Government. Department of Health and Ageing. Therapeutic Goods Administration. Product Information: Zocor (simvastatin, MSI). 2013. Available from https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMl?Openl:orm&t=pi&rq=simvastatin. Accessed 28 May 2013.
19. 14 Irishman W, Horn J. Statin-drug interactions, not a class effect. Cardiol Rev 2008; 16: 205-12.